Hepatitis, Viral, Human  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hepatitis, Viral, Human
NCT00096811: Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program

No Longer Available
N/A
RoW
Entecavir, Baraclude
Bristol-Myers Squibb
Hepatitis B, Chronic Disease
08/08
08/08
NCT02011932: Prospective Observational Study of Disease Progression in Chronic Hepatitis C

Active, not recruiting
N/A
133
RoW
Beijing YouAn Hospital
Hepatitis C, Chronic, Disease Progression, Liver Cirrhosis
06/11
07/30
NCT01508286 / 2010-023669-23: Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Checkmark BWG 2014: HEP3002
Aug 2014 - Aug 2014: BWG 2014: HEP3002
Checkmark BWG 2014: HEP3002
Aug 2014 - Aug 2014: BWG 2014: HEP3002
Checkmark HEP3002
More
No Longer Available
N/A
Europe, RoW
Telaprevir + peginterferon alfa + ribavirin, experimental, peginterferon alfa + ribavirin
Janssen-Cilag International NV
Hepatitis C
 
 
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Checkmark VHC 2015
Sep 2015 - Sep 2015: VHC 2015
Checkmark ILC 2015
Apr 2015 - Apr 2015: ILC 2015
Checkmark VHC 2014
More
No Longer Available
N/A
Europe
Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
NCT02161939: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Checkmark
Jul 2014 - Jul 2014: 
No Longer Available
N/A
US
Daclatasvir (BMS-790052), Sofosbuvir
Bristol-Myers Squibb
Chronic Hepatitis C
 
 
NCT01306071: Observational Study of Persons With Hepatitis B Virus Infection in North America

Recruiting
N/A
200
US
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
 
 
RELIF-C, NCT02865369: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

Not yet recruiting
N/A
103
RoW
Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks
Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb
Chronic Hepatitis C
12/18
12/22
NCT02793791: Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients

Not yet recruiting
N/A
30
RoW
minimally invasive ablation therapies
Shandong Cancer Hospital and Institute
Dysplastic Nodule of Liver, Chronic Hepatitis B
12/19
12/22
NCT03097952: "Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu

Recruiting
N/A
20000
RoW
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatitis B, Chronic
12/30
12/30

Download Options